



Acute Treatments for Migraine

Questions for Deliberation and Voting at the January 23rd Public Meeting

These questions are intended for the deliberation of the Midwest CEPAC voting body at the public meeting.

Clinical Evidence

Population for Questions 1-5: All adults patients with a diagnosis of migraine

1. Is the evidence adequate to demonstrate a net health benefit for treatment with lasmiditan compared with no treatment?

Yes

No

2. Is the evidence adequate to demonstrate a net health benefit for treatment with rimegepant compared with no treatment?

Yes

No

3. Is the evidence adequate to demonstrate a net health benefit for treatment with ubrogepant compared with no treatment?

Yes

No

4. Is the evidence adequate to distinguish the net health benefits between the gepants, rimegepant and ubrogepant?

Yes

No

- 4a. If the answer to Q4 is "Yes," which therapy has the greater net health benefit?

a) Rimegepant

b) Ubrogepant

5. Is the evidence adequate to distinguish the net health benefits between the gepants and lasmiditan? *(If yes to question 4, ask separately for each gepant.)*

Yes

No

5a. If the answer to Q5 is “Yes,” which therapy has the greater net health benefit?

a) Gepants

b) Lasmiditan

Population for Questions 6 and 7: Adult patients with a diagnosis of migraine who are eligible to use triptans.

6. Is the evidence adequate to distinguish the net health benefits between the gepants and triptans? *(If yes to question 4, ask separately for each gepant.)*

Yes

No

6a. If the answer to Question 6 is “Yes,” which therapy has the greater net health benefit?

a) Gepants

b) Triptans

7. Is the evidence adequate to distinguish the net health benefits between the lasmiditan and triptans?

Yes

No

7a. If the answer to Q7 is “Yes,” which therapy has the greater net health benefit?

a) Lasmiditan

b) Triptans

Potential Other Benefits or Disadvantages and Contextual Considerations

Population for Questions 8-11: *Adult patients with a diagnosis of migraine for whom triptans have not been effective, are not tolerated, or are contraindicated.*

8. Does treating patients with gepants offer one or more of the following “other benefits?” (select all that apply)
 - a. This intervention offers reduced complexity that will significantly improve patient outcomes.
 - b. This intervention will significantly reduce caregiver or broader family burden.
 - c. This intervention offers a novel mechanism of action or approach that will allow successful treatment of many patients for whom other available treatments have failed.
 - d. This intervention will have a significant impact on improving patients’ ability to return to work and/or their overall productivity.
 - e. There are other important benefits or disadvantages that should have an important role in judgments of the value of this intervention: _____

9. Does treating patients with lasmiditan offer one or more of the following “other benefits?” (select all that apply)
 - a. This intervention offers reduced complexity that will significantly improve patient outcomes.
 - b. This intervention will significantly reduce caregiver or broader family burden.
 - c. This intervention offers a novel mechanism of action or approach that will allow successful treatment of many patients for whom other available treatments have failed.
 - d. This intervention will have a significant impact on improving patients’ ability to return to work and/or their overall productivity.
 - e. There are other important benefits or disadvantages that should have an important role in judgments of the value of this intervention: _____

10. Are any of the following contextual considerations important in assessing gepants long-term value for money? (select all that apply)
 - a. This intervention is intended for the care of individuals with a condition of particularly high severity in terms of impact on length of life and/or quality of life.
 - b. This intervention is intended for the care of individuals with a condition that represents a particularly high lifetime burden of illness.
 - c. This intervention is the first to offer any improvement for patients with this condition.
 - d. There is significant uncertainty about the long-term risk of serious side effects of this intervention.

- e. There is significant uncertainty about the magnitude or durability of the long-term benefits of this intervention.
11. Are any of the following contextual considerations important in assessing lasmiditan long-term value for money? (select all that apply)
- a. This intervention is intended for the care of individuals with a condition of particularly high severity in terms of impact on length of life and/or quality of life.
 - b. This intervention is intended for the care of individuals with a condition that represents a particularly high lifetime burden of illness.
 - c. This intervention is the first to offer any improvement for patients with this condition.
 - d. There is significant uncertainty about the long-term risk of serious side effects of this intervention.
 - e. There is significant uncertainty about the magnitude or durability of the long-term benefits of this intervention.

Long-Term Value for Money

Population for Questions 12-14: *Adult patients with a diagnosis of migraine for whom triptans have not been effective, are not tolerated, or are contraindicated.*

12. Given the available evidence on comparative effectiveness and incremental cost-effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment with rimegepant versus no treatment?¹
- a. Low long-term value for money at current pricing
 - b. Intermediate long-term value for money at current pricing
 - c. High long-term value for money at current pricing
13. Given the available evidence on comparative effectiveness and incremental cost-effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment with ubrogepant versus no treatment?²

¹ Rimegepant value votes will be taken only if the therapy price has been announced by the time of the January 23 public meeting.

² Ubrogapant value votes will be taken only if the therapy price has been announced by the time of the January 23 public meeting.

- a. Low long-term value for money at current pricing
 - b. Intermediate long-term value for money at current pricing
 - c. High long-term value for money at current pricing
14. Given the available evidence on comparative effectiveness and incremental cost-effectiveness, and considering other benefits, disadvantages, and contextual considerations, what is the long-term value for money of treatment with lasmiditan versus no treatment?³
- a. Low long-term value for money at current pricing
 - b. Intermediate long-term value for money at current pricing
 - c. High long-term value for money at current pricing

³ Lasmiditan value votes will be taken only if the therapy price has been announced by the time of the January 23 public meeting.